Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells (original) (raw)

References

1. Redner RL, Wang J, Liu JM . Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999; 94: 417–428.
   CAS PubMed Google Scholar
2. Blobel GA . CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood 2000; 95: 745–755.
   CAS PubMed Google Scholar
3. Marcucci G, Caligiuri MA, Bloomfield CD . Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest 2000; 18: 768–780.
   Article CAS PubMed Google Scholar
4. Lutterbach B, Hiebert SW . Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene 2000; 245: 223–235.
   Article CAS PubMed Google Scholar
5. Speck NA, Stacy T, Wang Q, North T, Gu TL, Miller J, Binder M, Marin-Padilla M . Core-binding factor: a central player in hematopoiesis and leukemia. Cancer Res 1999; 59: 1789s–1793s.
   CAS PubMed Google Scholar
6. Uchida H, Zhang J, Nimer SD . AML1A and AML1B can transactivate the human IL-3 promoter. J Immunol 1997; 158: 2251–2258.
   CAS PubMed Google Scholar
7. Erickson PF, Dessev G, Lasher RS, Philips G, Robinson M, Drabkin HA . ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Blood 1996; 88: 1813–1823.
   CAS PubMed Google Scholar
8. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM . ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 1998; 95: 10860–10865.
   Article CAS PubMed PubMed Central Google Scholar
9. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW . ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 1998; 18: 7176–7184.
   Article CAS PubMed PubMed Central Google Scholar
10. Gelmett V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA . Aberrant recruitment of the nuclear receptor corepressor–histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998; 18: 7185–7191.
    Article Google Scholar
11. Pandolfi PP . Histone deacetylases and transcriptional therapy with their inhibitors. Chemother Pharmacol Cancer 2001; 48: S17–S19.
    Article CAS Google Scholar
12. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K . FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994; 47: 315–323.
    Article CAS Google Scholar
13. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M . Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem 1994; 58: 1579–1583.
    Article CAS PubMed Google Scholar
14. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S . FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998; 241: 126–133.
    Article CAS PubMed Google Scholar
15. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR . Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells [published erratum appears in Blood 2000 Jan 15;95(2):409]. Blood 1999; 94: 1401–1408.
    CAS PubMed Google Scholar
16. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE . Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718–728.
    CAS PubMed Google Scholar
17. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE . Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001; 98: 2865–2868.
    Article CAS PubMed Google Scholar
18. Bruner RJ, Marcucci G, Binkley P, Fischer B, Parthun M, Davis M, Xiao J, Chan K, Wright J, Grever MR, Byrd JC . A phase I study to determine minimally effective pharmacologic dose (MEPF) of depsipeptide (FR901228) in selected hematologic malignancies. Proc Am Soc Clin Oncol 2002; 21: 265A.
    Google Scholar
19. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N . Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991; 77: 2031–2036.
    CAS PubMed Google Scholar
20. Parthun MR, Widom J, Gottschling DE . The major cytoplasmic histone acetyltransferase in yeast: links to chromatin replication and histone metabolism. Cell 1996; 87: 85–94.
    Article CAS PubMed Google Scholar
21. Marcucci G, Caligiuri MA, Dohner H, Archer KJ, Schlenk RF, Dohner K, Maghraby EA, Bloomfield CD . Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 2001; 15: 1072–1080.
    Article CAS PubMed Google Scholar
22. Lai CK, Ho SS, Chan CH, Leung R, Lai KN . Gene expression of interleukin-3 and granulocyte macrophage colony-stimulating factor in circulating CD4+ T cells in acute severe asthma. Clin Exp Allergy 1996; 26: 138–146.
    Article CAS PubMed Google Scholar
23. Marcucci G, Strout MP, Bloomfield CD, Caligiuri MA . Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts. Cancer Res 1998; 58: 790–793.
    CAS PubMed Google Scholar
24. Bestor TH . Gene silencing. Methylation meets acetylation. Nature 1998; 393: 311–312.
    Article CAS PubMed Google Scholar
25. Ng HH, Bird A . DNA methylation and chromatin modification. Curr Opin Genet Dev 1999; 9: 158–163.
    Article CAS PubMed Google Scholar
26. Wang J, Saunthararajah Y, Redner RL, Liu JM . Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res 1999; 59: 2766–2769.
    CAS PubMed Google Scholar
27. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, Mancini M, Pelicci PG, Lo Coco F, Nervi C . Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001; 61: 2–7.
    PubMed Google Scholar
28. Turner BM . Histone acetylation and an epigenetic code. Bioessays 2000; 22: 836–845.
    Article CAS PubMed Google Scholar
29. Akhtar A, Becker P . Activation of transcription through histone H4 acetylation by MOF, an acetyltransferase essential for dosage compensation in Drosophila. Mol Cell 2000; 5: 367–375.
    Article CAS PubMed Google Scholar
30. Smith E, Pannuti A, Gu W, Steurnagel A, Cook R, Allis C, Lucchesi J . The drosophila MSL complex acetylates histone H4 at lysine 16, a chromatin modification linked to dosage compensation. Mol Cell Biol 2000; 20: 312–318.
    Article CAS PubMed PubMed Central Google Scholar
31. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, Pelicci PG . Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295: 1079–1082.
    Article CAS PubMed Google Scholar
32. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB . Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103–107.
    Article CAS PubMed Google Scholar

Download references